OncoSec Medical Inc.
200 South Virginia Street
396 articles with OncoSec Medical Inc.
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), today announced the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer.
OncoSec Medical Incorporated, a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, announced the appointment of George Chi as Chief Financial Officer.
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), today announced that Margaret Dalesandro, Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi, M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair.
OncoSec Medical Incorporated will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino , MD
OncoSec Medical Incorporated today announced that Chris Twitty , Ph.D., Chief Scientific Officer,
OncoSec Medical Incorporated announced the establishment of a Leadership Committee consisting of three board members, Margaret Dalesandro, Ph.D., Herbert Kim Lyerly, M.D. and Yuhang Zhao, Ph.D., MBA, to lead all development efforts, with a focus on the Company's lead asset, TAVO™.
OncoSec Medical Incorporated today announced that Interim CEO and Chief Operating Officer, Brian Leuthner , and Senior Vice President, Chief Clinical Development Officer, Sandra Aung , Ph.D., will participate in a fireside chat at the BTIG Virtual Biotechnology Conference
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
Mr. Silverman joins OncoSec with over two decades of electroporation device quality and manufacturing experience.
- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21 st – Wednesday, June 23 rd , 2021.
Biotech industry veteran brings over 20 years of project and alliance management experience largely focused on oncology and clinical development
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device GenPulse™ for the Treatment of Solid Tumors
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it has received authorization to CE mark its proprietary next generation go-to-market gene delivery device, GenPulse™, a part of the OncoSec Medical System (OMS) electroporation device platform for use in solid tumors.
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
Results From ILLUMINATE-301 To Be Discussed Webinar To Be Held on Wednesday, March 31, 2021 at 12:00 p.m. ET.
Biotech industry veteran brings more than 15 years of clinical development and leadership experience largely focused on Oncology, including the combination of cytokines and check-point inhibitors
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the addition of two new executives to the company's management team. Industry veteran Brian Leuthner has been appointed as OncoSec's Chief Operating Officer and Joe Smith has joined as Vice President of Business Development
OncoSec Medical Incorporated, a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
-- Expanded access program enables patient with immune checkpoint inhibitor resistant metastatic melanoma to be treated with TAVOTM + pembrolizumab -- Patient with widely disseminated disease achieves responses in visceral tumors after extensive history of treatment failures
OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment
-- Significance of 30% overall response rate (ORR), 6% complete responses (CR), durability and favorable safety data from KEYNOTE-695 Phase 2b trial discussed by Key Opinion Leaders (KOLs) specializing in melanoma treatment --
OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it will host an Investor and Analyst webinar on Wednesday, November 11, 2020 from 8:30 am ET – 10:00 am ET showcasing interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAV